fashion -WSS

fashion

author：comprehensive 2025-08-05 16:44:21 Page View：12

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Former Pear Therapeutics executives start new VC firm
Next article： Tori Bowie and the unacceptable rates of Black maternal death

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

NYU Langone launches private ChatGPT for its health care data

VincentMajor(left)andCristinaGonzalezattheprompt-a-thonorganizedbyNYULangone.CourtesyJoeCarrotta/NYU

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

PBMs are inflating the cost of generic drugs. They must be reined in

AdobeThesearenotcomfortabledaysinWashingtonforpharmacybenefitmanagers,thehighlyconsolidatedgroupofin

fashion

explore

knowledge

PBMs are inflating the cost of generic drugs. They must be reined in